Abstract
[Hubei Pharmaceutical: Cannot guarantee the normal supply of ibuprofen sustained-release capsules and waive the qualification for selection in Shandong Province]On August 22, North China Pharmaceutical announced that after the company’s ibuprofen sustained-release capsules were selected, although the company actively took relevant measures, However, due to insufficient existing production capacity, insufficient attention by the responsible units, relevant registration and change policy adjustments, and the impact of the epidemic, the company cannot guarantee normal supply. After communicating with the Shandong Provincial Medical Security Bureau, the company proposed to give up the qualification, and Shandong Province invited other companies to make up the bid for the product. In the next step, the company will accelerate the progress of the approval process for the expansion project of ibuprofen sustained-release capsules, and strive to complete the approval before the end of September. After the expansion, the annual production capacity is expected to reach 100 million capsules, and to strengthen communication with other selected provinces of the product. Go all out to ensure the supply of this product in other selected provinces. (Interface News)
August 22nd, newsNorth China PharmaceuticalAnnouncementAfter the company’s ibuprofen sustained-release capsules were selected, although the company actively took relevant measures, due to insufficient existing production capacity, the responsible unit did not pay enough attention to it, related registration and change policy adjustments, and the impact of the epidemic, resulting in the company’s failure to guarantee normal supply.
In order to minimize the impact on the centralized procurement and supply of Shandong Province, the company proposed to waive the qualifications after communicating with the Shandong Provincial Medical Security Bureau in August 2021, and Shandong Province invited other companies to make up for the product.
Recently, the Shandong Provincial Medical Security Bureau has identified a replacement company in accordance with the relevant procedures, and the replacement company will continue to supply it.
In the next step, the company will accelerate the progress of the approval process for the expansion project of ibuprofen sustained-release capsules, and strive to complete the approval before the end of September. After the expansion, the annual production capacity is expected to reach 100 million capsules, and to strengthen communication with other selected provinces of the product. Go all out to ensure the supply of this product in other selected provinces.
(Article Source: Interface News)
.